Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome.
Mabrey FL, Gardner KM, Shannon Dorcy K, Perdue A, Smith HA, Davis AM, Hammer C, Rizzuto D, Jones S, Quach K, Scott BL, Hendrie PC, Percival MM, Walter RB, Appelbaum FR, Estey EH, Becker PS. Mabrey FL, et al. Among authors: perdue a. Blood Adv. 2020 Feb 25;4(4):611-616. doi: 10.1182/bloodadvances.2019000707. Blood Adv. 2020. PMID: 32074276 Free PMC article.
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Tachiki LML, Hippe DS, Williams Silva K, Hall ET, McCamy W, Fritzsche D, Perdue A, Majovski J, Pulliam T, Goldstein DA, Veatch J, Ho J, Nghiem PT, Thompson JA, Bhatia S. Tachiki LML, et al. Among authors: perdue a. Cancer Immunol Immunother. 2023 Nov;72(11):3839-3850. doi: 10.1007/s00262-023-03539-8. Epub 2023 Sep 21. Cancer Immunol Immunother. 2023. PMID: 37733060 Free PMC article.
Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Tachiki LML, Hippe DS, Silva KW, Hall ET, McCamy W, Fritzsche D, Perdue A, Majovski J, Pulliam T, Goldstein DA, Veatch J, Ho J, Nghiem PT, Thompson JA, Bhatia S. Tachiki LML, et al. Among authors: perdue a. Cancer Immunol Immunother. 2023 Dec;72(12):4471. doi: 10.1007/s00262-023-03575-4. Cancer Immunol Immunother. 2023. PMID: 37979010 Free PMC article. No abstract available.
The rate of disuse osteopenia in admitted, non-weight-bearing patients.
Walley KC, Farrar NR, Muralidharan A, Monovoukas DA, Eichman J, Klueh MP, Baumann AN, Perdue AM, Hake ME, Ahn J. Walley KC, et al. Among authors: perdue am. J Orthop Res. 2024 Apr;42(4):806-810. doi: 10.1002/jor.25713. Epub 2023 Oct 14. J Orthop Res. 2024. PMID: 37804218
33 results